ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Telmisartan

Also written as “telmisartan”, “CKD-828, D097, D337” and “Telmisartan 40 mg”.

Its studies are mostly in Hypertension · Essential Hypertension · Diabetic Nephropathies · Hypercholesterolemia · Hyperlipidemias, led by 15 companies.

Drug pageTelmisartan: every studyMany companies study it; this page follows only the 130 they lead. All 177 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 2, 2002130 company-led studies, 4 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheimits history only900 open or runningphase 4since May 2, 2002May 2, 2002none ahead
Chong Kun Dang Pharmaceuticalits history only122 open or runningphase 4since Mar 9, 2023May 20, 2010none ahead
Yuhanits history only81 open or runningphase 4since Nov 10, 2016May 29, 2014none ahead
IlDong Pharmaceuticalits history only40 open or runningphase 3since Mar 5, 2014Mar 5, 2014none ahead
Jeil Pharmaceuticalits history only30 open or runningphase 3since Mar 8, 2017Mar 9, 2015none ahead
Daewon Pharmaceuticalits history only20 open or runningphase 3since Oct 12, 2016Oct 12, 2016none ahead
George Medicines PTYits history only20 open or runningphase 3since Aug 15, 2020Aug 15, 2020none ahead
HK inno.Nits history only20 open or runningphase 1since Aug 25, 2021Aug 25, 2021none ahead
Daewoong Pharmaceuticalits history only10 open or runningphase 1since Mar 4, 2013Mar 4, 2013none ahead
DongKoo Bio & Pharmaits history only10 open or runningphase 1since Feb 8, 2018Feb 8, 2018none ahead
THPharm10 open or runningphase 1since Sep 8, 2023Sep 8, 2023none ahead

Also a collaborator on its studies: Linical Korea, GlaxoSmithKline and Bayer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of THPharm only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2023First study: phase 1 study in HypertensionFirst studyNCT06063109 · 51 enrolled · South Korea

TargetBeta

AGTR1 →read by rule
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule

Other programs on AGTR1

ProgramCompanyFurthest phaseStudies
ValsartanruleNovartisphase 4145
LosartanruleOrganonphase 458
azilsartan medoxomilruleTakedaphase 425
sparsentanruletravere-therapeutics-incphase 49

Studies

The one study THPharm leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06063109Hypertension · South Korea1CompletedNov 9, 202351

How it is read

Names in the registry

  • “Telmisartan”, 38 entries
  • “telmisartan”, 7 entries
  • “CKD-828, D097, D337”, 6 entries
  • “Telmisartan 40 mg”, 6 entries
  • “Low dose of telmisartan”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.